Giant prolactinoma, germline BRCA1 mutation, and depression: A case report 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
| Autor: | Bettencourt-Silva, R, Queirós, J, Pereira, J, Carvalho, D |
|---|---|
| Přispěvatelé: | Instituto de Investigação e Inovação em Saúde |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Antidepressive Agents / therapeutic use Magnetic Resonance Imaging / methods Depressive Disorder / complications Mutation / genetics BRCA1 Protein / genetics Prolactinoma / diagnostic imaging Pituitary Neoplasms / complications Dopamine Agonists / therapeutic use Cabergoline / therapeutic use Depressive Disorder / drug therapy Humans Prolactinoma / therapy Female Prolactinoma / complications Pituitary Neoplasms / therapy Pituitary Neoplasms / diagnostic imaging |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| Popis: | Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition. Case presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. She also had a breast cancer gene 1 (BRCA1) mutation and a family history of breast cancer. She had marked hyperprolactinemia (7615 ng/dL), central hypocortisolism, growth hormone deficiency, and a giant pituitary tumor (52 × 30 × 33 mm) which was shown in magnetic resonance imaging with obstructive hydrocephalus, requiring emergency surgery. Treatment with cabergoline led to a 99.8% reduction in serum prolactin levels and significant tumor shrinkage. Her depressive symptoms progressively improved and psychiatric drugs were withdrawn after 3 months of cabergoline treatment. Currently, she is being followed in Endocrinology, Neurosurgery, and Neurophthalmology out-patient clinics and in a breast cancer unit. Careful monitoring, support, and follow-up will be essential throughout this patient's life. Conclusions: This case is a rare presentation of a giant prolactinoma in a young woman, who presented a life-threatening event. She also had an unexpected association between diseases or symptoms that may have contributed to the delay in diagnosis. Given the concomitant presence of a giant prolactinoma, a BRCA1 mutation, and depressive symptoms, a possible association was hypothesized. The breast cancer risk in a BRCA1 mutation carrier and the possible interference of hyperprolactinemia and life events were also discussed. However this hypothesis requires further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|